Treating sufferers with mixture remedy approaches might enhance survival for sufferers with EGFR-positive lung most cancers compared with monotherapy treamtents, similar to giving Tagrisso (osimertinib) alone, Dr. Edgardo Santos stated in an interview with CURE.
Santos, medical director of the Broward County Oncology Institute of Hope and Innovation in Florida, mentioned latest knowledge from the FLAURA2 and MARIPOSA trials. In FLAURA2, Tagrisso plus chemotherapy outperformed Tagrisso alone, whereas MARIPOSA confirmed that Rybrevant (amivantamab) plus Leclaza (lazertinib), a chemotherapy-free possibility, additionally offered a survival profit.
Santos defined that for six years, Tagrisso monotherapy was the usual, however these outcomes now push physicians to guage whether or not sufferers might profit extra from monotherapy or a mixture method, relying on danger elements.
Transcript
What are the potential advantages of taking Tagrisso alone versus combining it with different therapies?
Tagrisso turned the popular agent in our tips again in 2019 based mostly on a medical trial referred to as FLAURA. Because the years have handed, extra analysis has come ahead, and right now we’ve two different therapies that use mixture approaches.
One in all them was offered right now on the IASLC 2025 World Convention on Lung Most cancers: the FLAURA2 trial. FLAURA2 confirmed an general survival profit. This [study evaluated] the mixture of Tagrisso plus chemotherapy versus Tagrisso alone.
The opposite examine, MARIPOSA, additionally confirmed a optimistic general survival profit with a chemotherapy-free mixture. This entails Leclaza plus Rybrevant, a monoclonal antibody. That mixture additionally confirmed superiority over Tagrisso alone.
So, right now, when a affected person involves the clinic, I at all times encourage them to speak with their thoracic or medical oncologist about all choices. For the previous six years, Tagrisso alone was the usual. Now, we as physicians want to debate whether or not a affected person is a candidate for monotherapy or if mixture remedy is extra applicable. Based mostly on danger elements and findings from these two newest research, MARIPOSA and FLAURA2, we are actually capable of higher establish high-risk options in sufferers with EGFR mutations.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling,
